Prelude Therapeutics
PRLD
55 hedge funds and large institutions have $105M invested in Prelude Therapeutics in 2026 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 20 increasing their positions, 11 reducing their positions, and 5 closing their positions.
469% more call options, than puts
Call options by funds: $91K | Put options by funds: $16K
160% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 5
82% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 11
27% more capital invested
Capital invested by funds: $82.6M → $105M (+$22.7M)
15% more funds holding
Funds holding: 48 → 55 (+7)
16.21% less ownership
Funds ownership: 65.06% → 48.84% (-16%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$2.48M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$2.11M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.14M |
| 4 |
Millennium Management
New York
|
+$608K |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$401K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.19M |
| 2 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$466K |
| 3 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$200K |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$112K |
| 5 |
OAC
OMERS Administration Corp
Toronto,
Ontario, Canada
|
-$106K |
PRLD Hedge Fund Activity: Q1 2026 in Review
55 of the 8,201 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q1 2026, worth a combined $105M — up 27% from $82.6M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new PRLD positions and 5 closed out — a net gain of 8 holders — while 20 added to existing stakes and 11 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $2.48M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $2.19M sold.
- 55 institutional investors held Prelude Therapeutics (PRLD) as of Q1 2026, up from 48 in Q4 2025.
- Funds reported $105M of Prelude Therapeutics stock for Q1 2026, up 27% quarter-over-quarter.
- 13 funds opened new Prelude Therapeutics positions in Q1 2026 and 5 closed out, a net change of +8 holders.
- The largest Prelude Therapeutics buyer in Q1 2026 was EcoR1 Capital, an estimated $2.48M added.
- The largest Prelude Therapeutics seller in Q1 2026 was T. Rowe Price Associates, an estimated $2.19M sold.
Based on aggregated 13F filings for Q1 2026.